Review the epidemiology and pathophysiology of CTD, and how it places patients at high risk for secondary PAH
|
|
|
|
|
|
Discuss how to use appropriate screening and diagnostic criteria to identify patients with CTDs who may have PAH
|
|
|
|
|
|
Describe how to determine if patients should be referred for cardiac catheterization and definitively diagnose PAH
|
|
|
|
|
|
Outline how to integrate guideline recommendations and efficacy and safety data of PAH pharmacotherapies for treatment of patients with CTD-PAH
|
|
|
|
|
|
Describe how to apply a collaborative approach across multidisciplinary experts to optimize outcomes for patients with CTD-PAH
|
|
|
|
|
|